AbbVie Just Dropped $650M on a Cancer Drug That Doesn't Exist Yet
AbbVie wired $650 million to Chinese biotech RemeGen for a cancer drug still in phase 2 trials, with the total deal potentially worth $5.6 billion. It's a massive bet that bispecific antibodies will reshape oncology, and AbbVie isn't the only one racing to find out.
The Check Cleared Before the Data Did
Imagine writing a $650 million check for a restaurant that's still testing recipes. That's roughly what AbbVie just did in oncology.
The pharma giant inked an exclusive licensing deal with Chinese biotech RemeGen for RC148, a bispecific antibody that simultaneously targets two of cancer's biggest vulnerabilities. The asset is still in phase 2 trials in China, with only early hints of clinical promise. And yet AbbVie wired $650 million upfront, with the total deal potentially worth up to $5.6 billion when you add development, regulatory, and commercial milestones.
The announcement dropped at the J.P. Morgan 2026 Healthcare Conference, and it tells you everything about where big pharma thinks cancer treatment is heading.
Two Birds, One Antibody
So what exactly is RC148? Think of it as a molecular multitasker.
Most cancer drugs hit one target. RC148 hits two at once. It blocks PD-1, an immune checkpoint that tumors exploit to hide from your immune system, while also neutralizing VEGF, a protein that tumors use to grow their own blood supply. PD-1 is the same pathway behind blockbuster drugs like Keytruda and Opdivo. VEGF inhibitors like Avastin have been around for two decades.
The twist: instead of giving patients two separate drugs (with two sets of side effects and two infusion appointments), a bispecific antibody wraps both functions into a single molecule. It's like a combo lock that turns two tumblers simultaneously. Block PD-1, and the immune system wakes up. Block VEGF, and the tumor's supply lines get cut.
Early clinical studies show "initial favorable antitumor activity," particularly when RC148 is paired with antibody-drug conjugates (ADCs), which are basically guided missiles that deliver chemotherapy directly to cancer cells. AbbVie's pitch is that RC148 could make its own ADC pipeline work even better, a one-plus-one-equals-three argument that clearly convinced someone to authorize a very large wire transfer.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
This deal doesn't exist in a vacuum. AbbVie has been on an oncology shopping spree.
In February 2024, the company closed its $10.1 billion acquisition of ImmunoGen, bringing in Elahere (an approved ovarian cancer drug) and a pipeline of ADCs. It also co-develops Epkinly, a bispecific antibody for blood cancers, with Genmab. The RemeGen partnership is the next piece of a deliberate strategy: build a "modality stack" of ADCs, bispecifics, and combinations that can attack solid tumors from multiple angles.
AbbVie's Vice President, Therapeutic Area Head for Oncology, Solid Tumor and Hematology, Daejin Abidoye, framed it explicitly: "By combining the immune checkpoint inhibition and anti-angiogenic activity of RC148 together with the targeted cytotoxic activity of ADCs, we have the potential to identify meaningful options for patients across a range of solid tumors."
Translation: we want to pair this bispecific with our guided-missile drugs and see if the combo is better than anything on the market. The company is already eyeing combinations with its investigational ADC telisotuzumab adizutecan for non-small cell lung cancer and colorectal cancer.
With Humira's patent cliff firmly in the rearview mirror, AbbVie needs oncology wins badly. The immunology franchise (Skyrizi and Rinvoq) is carrying the load for now, but cancer drugs offer the kind of premium pricing and long product lifecycles that keep shareholders happy.
The $5.6 Billion Question: Is RC148 Worth It?
The deal's structure tells a nuanced story. That $650 million upfront is real money, no doubt. But the remaining $4.95 billion in milestones only pays out if RC148 clears a long series of hurdles: successful trials, regulatory approvals, and commercial sales targets. Plus tiered double-digit royalties on net sales outside Greater China, where RemeGen keeps the rights.
In other words, AbbVie paid a hefty cover charge to get into the club, but the truly expensive bottles only arrive if the party delivers.
The risk? RC148 is still in phase 2. No detailed efficacy data (response rates, survival numbers) has been made public. The FDA has cleared the IND application, which means AbbVie can start running trials outside China, but that's a green light to begin, not a guarantee of success. Phase 2 oncology assets fail more often than they succeed.
The reward? If RC148 works, AbbVie would have a bispecific antibody that enhances its entire ADC portfolio across multiple tumor types. That's not just one product; it's a platform play.
A Crowded Race With Very High Stakes
AbbVie isn't the only pharma company that sees gold in PD-1/VEGF bispecifics. The field has gotten remarkably crowded, remarkably fast.
Pfizer has PF-08634404 in development. BioNTech and Bristol Myers Squibb are advancing pumitamig, which showed encouraging phase 2 data in triple-negative breast cancer in 2025. Akeso (partnered with Summit Therapeutics) is pushing ivonescimab through multiple trials. Crescent Biopharma dosed its first patient in a phase 1/2 trial just last month. The field is crowded with numerous trials evaluating PD-1/VEGF bispecifics across cancer indications.
That's not a pipeline; it's a stampede. And the clinical data from these competitors will ultimately determine whether AbbVie's $650 million bet looks brilliant or premature.
The China Factor
This deal also reinforces a trend that's impossible to ignore: US pharma's growing dependence on Chinese biotech innovation.
Chinese firms out-licensed a staggering $135 billion worth of deals in 2025, up significantly from $51.9 billion in 2024. The average upfront payment for Western-Chinese biotech deals has climbed 230% since 2022, rising to $172 million so far in 2026.
The geopolitical backdrop makes this complicated. The BIOSECURE Act restricts certain federal biotech contracts but doesn't touch private licensing deals. Tariffs, Taiwan tensions, and proposals for new oversight mechanisms (including CFIUS-style reviews for licensing) loom in the background. Yet the deal flow keeps accelerating because the economics are irresistible: China produces high-quality early-stage assets at a pace and cost that US biotechs struggle to match.
AbbVie, like its peers, is placing the bet that innovation doesn't carry a passport.
The Bottom Line
AbbVie's $650 million check to RemeGen is a high-conviction wager on two ideas. First, that bispecific antibodies combining PD-1 and VEGF blockade will become foundational in cancer treatment. Second, that pairing these bispecifics with ADCs will create combinations powerful enough to justify the price tag.
The data to prove either thesis doesn't fully exist yet. But in a field where numerous competitors are racing toward the same finish line, AbbVie decided that showing up late would cost more than showing up early. Whether that logic holds will depend on phase 3 results that are still years away.
Sometimes the biggest risk isn't writing the check. It's waiting too long to write it.
Deals & M&A4 min read
Gilead Just Paid $7.8B for a Protein the Size of a Paperclip
Gilead is spending $7.8 billion to acquire Arcellx and its next-gen CAR-T therapy for multiple myeloma. The secret weapon? A synthetic protein one-third the size of what competitors use, with clinical data that might just be best-in-class.
